Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
← catalyst calendarNCT06717438 · readout in 498 d
Sponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
30actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-13 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Jordan's Syndrome
- PPP2R5D Neurodevelopmental Disorder
Interventions
- Drug: BPN14770 — also filed as Zatolmilast
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange From Baseline at Week 24 in Numerical Rating Scale Within the Domain of Language/Communication
measured Baseline, Week 24
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
measured Day 1 up to Week 96
Discontinuation-emergent Signs and Symptoms (DESS) Questionnaire Score
measured Week 98
Number of Participants with Seizures
measured Up to Week 96
Number of Participants at Suicidality Risk
measured Up to Week 96
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed